All News

Expert discusses groundbreaking studies on the on-body injector for isatuximab, highlighting its efficacy, safety, and patient convenience.

Explore the evolving landscape of biological medicine, focusing on quality standards and innovations in cell and gene therapies for chronic diseases.

Pharmacists enhance patient care in multiple myeloma by focusing on infection prevention, CRS management, and optimizing outcomes with T-cell engagers post-CAR T.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Careful selection of pharmacotherapy and close monitoring are crucial to ensuring safety and efficacy.

The indication is for the treatment of adult and pediatric patients who weigh at least 30 kg.

Pharmacists are key to closing care gaps and supporting long-term recovery.

Guselkumab becomes the first and only IL-23 inhibitor with a fully subcutaneous induction regimen for adults with ulcerative colitis.

Fast-melt tablets may help improve adherence by offering patients a convenient alternative to traditional pills, especially for those experiencing pill fatigue or managing multiple medications.

Costimulatory bispecific antibodies revolutionize multiple myeloma treatment, offering deeper responses and flexible sequencing strategies for patients.

New findings reveal that combining daratumumab with lenalidomide significantly enhances MRD negativity and progression-free survival in multiple myeloma maintenance therapy.

Linvoseltamab combined with carfilzomib shows promising results in treating relapsed/refractory multiple myeloma.

The approval is supported by findings from the MK-3475A-D77 study.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend that COVID-19 vaccines be administered through individual-based decision-making.

AI is redefining the workforce by enhancing care and efficiency.

Discover effective strategies for managing eczema, dry skin, sun protection, and acne with expert recommendations for OTC treatments.

Experts discuss the potential of linvoseltamab in treating high-risk smoldering multiple myeloma, highlighting promising early trial results and response rates.

Expert highlights how taste-masking, dose, and particle size influence patient adherence and the clinical performance of fast-dissolving delivery systems.

A multicenter registry analysis reveals that high-risk cardiovascular patients often miss opportunities to receive pneumococcal and influenza vaccinations, showcasing gaps that could be filled by pharmacists.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

The BMJ study highlights that young children vaccinated against influenza in October experience the greatest protection, with lower infection rates than those vaccinated earlier.

Members of the Advisory Committee on Immunization Practices (ACIP) voted to restrict the combined measles, mumps, rubella, and varicella (MMRV) vaccine and hepatitis B vaccine for certain age groups.

With this approval, an effective, nonsteroidal treatment option is available for young patients.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.

Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

The latest antibiotic therapies and guidelines offer effective strategies for managing carbapenem-resistant Acinetobacter baumannii infections